PTC Therapeutics vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

PTC Therapeutics Inc (PTCT)

Q3 20262 Jul – 13 Aug 2026

▲3▼1

PTC's Sephience Launch Drives Record Revenue, Raised Guidance, and Pipeline Expansion

Sephience launch momentum PTC's PKU drug Sephience generated $151 million in Q2 2026, up 21% from Q1, with 1,647 patients on therapy. The launch is ahead of expectations, driving product revenue and supporting the raised full-year guidance.
Sephience is the main growth engine and the key reason for the raised guidance and record revenue.
Record Q2 revenue and raised guidance PTC reported record Q2 revenue of $361 million, more than doubling product revenue, and raised full-year product revenue guidance to $850–950 million. Management expects cash flow breakeven in 2026, with $2.23 billion in cash.
The earnings beat and guidance raise are the period's biggest fundamental news, directly affecting valuation.
Acquisition of ST-920 gene therapy for Fabry disease PTC agreed to acquire ST-920, a late-stage gene therapy for Fabry disease, for $111 million upfront plus milestones. The deal expands the pipeline and leverages PTC's rare disease commercial infrastructure, targeting a 2027 launch.
This is a new strategic move that adds a near-term pipeline asset and potential future revenue.
Competitive threat to Emflaza from Catalyst's Agamree Catalyst's Agamree showed comparable efficacy to PTC's Emflaza with less immunosuppression in a phase I study, potentially threatening Emflaza's market position. Emflaza contributed $25 million in Q2, a small but declining part of PTC's portfolio.
This is a real competitive risk that could pressure Emflaza sales, though it is a minor part of PTC's overall revenue.

July 20262 Jul – 13 Aug 2026

▲3▼1

PTC's Sephience Launch Drives Record Revenue, Raised Guidance, and Pipeline Expansion

Sephience launch momentum PTC's PKU drug Sephience generated $151 million in Q2 2026, up 21% from Q1, with 1,647 patients on therapy. The launch is ahead of expectations, driving product revenue and supporting the raised full-year guidance.
Sephience is the main growth engine and the key reason for the raised guidance and record revenue.
Record Q2 revenue and raised guidance PTC reported record Q2 revenue of $361 million, more than doubling product revenue, and raised full-year product revenue guidance to $850–950 million. Management expects cash flow breakeven in 2026, with $2.23 billion in cash.
The earnings beat and guidance raise are the period's biggest fundamental news, directly affecting valuation.
Acquisition of ST-920 gene therapy for Fabry disease PTC agreed to acquire ST-920, a late-stage gene therapy for Fabry disease, for $111 million upfront plus milestones. The deal expands the pipeline and leverages PTC's rare disease commercial infrastructure, targeting a 2027 launch.
This is a new strategic move that adds a near-term pipeline asset and potential future revenue.
Competitive threat to Emflaza from Catalyst's Agamree Catalyst's Agamree showed comparable efficacy to PTC's Emflaza with less immunosuppression in a phase I study, potentially threatening Emflaza's market position. Emflaza contributed $25 million in Q2, a small but declining part of PTC's portfolio.
This is a real competitive risk that could pressure Emflaza sales, though it is a minor part of PTC's overall revenue.

Latest2 Jul – 13 Aug 2026

▲3▼1

PTC's Sephience Launch Drives Record Revenue, Raised Guidance, and Pipeline Expansion

Sephience launch momentum PTC's PKU drug Sephience generated $151 million in Q2 2026, up 21% from Q1, with 1,647 patients on therapy. The launch is ahead of expectations, driving product revenue and supporting the raised full-year guidance.
Sephience is the main growth engine and the key reason for the raised guidance and record revenue.
Record Q2 revenue and raised guidance PTC reported record Q2 revenue of $361 million, more than doubling product revenue, and raised full-year product revenue guidance to $850–950 million. Management expects cash flow breakeven in 2026, with $2.23 billion in cash.
The earnings beat and guidance raise are the period's biggest fundamental news, directly affecting valuation.
Acquisition of ST-920 gene therapy for Fabry disease PTC agreed to acquire ST-920, a late-stage gene therapy for Fabry disease, for $111 million upfront plus milestones. The deal expands the pipeline and leverages PTC's rare disease commercial infrastructure, targeting a 2027 launch.
This is a new strategic move that adds a near-term pipeline asset and potential future revenue.
Competitive threat to Emflaza from Catalyst's Agamree Catalyst's Agamree showed comparable efficacy to PTC's Emflaza with less immunosuppression in a phase I study, potentially threatening Emflaza's market position. Emflaza contributed $25 million in Q2, a small but declining part of PTC's portfolio.
This is a real competitive risk that could pressure Emflaza sales, though it is a minor part of PTC's overall revenue.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.